Kyntra Bio cuts royalty obligation by $60m in balance sheet overhaul
Kyntra Bio (Nasdaq: KYNB) has restructured its royalty financing agreement with NQ Project Phoebus, L.P., paying $42.6 million upfront to reduce the maximum aggregate payments under the deal from $125 million to $65 million. The move cuts the company's outstanding payment obligations by $60 million and forms part of what management describes as a deliberate, multi-year effort to simplify its financial position.
The accelerated payment brings total cash transferred to NQ Project Phoebus to $50 million, which the San Francisco-based company says constitutes a full return of the counterparty's invested capital. Up to $15 million in additional payments remain, to be funded from 50% of the revenues Kyntra receives from its partner Astellas across the Astellas territories, excluding Japan. Once that $15 million cap is met, the agreement terminates and Kyntra retains all subsequent royalties on EVRENZO in those markets.
Balance sheet context
Chief financial officer David DeLucia framed the amendment as the latest in a sequence of balance sheet actions. In 2025, the company divested its China operations and retired a senior secured term loan. Earlier this year, its Finnish subsidiary FibroGen Europe filed for voluntary bankruptcy and ultimately settled liabilities of approximately $19.2 million for around $0.1 million, generating a material non-operating gain in the second quarter of 2026. Taken together, those moves and the current amendment have removed roughly $80 million in future liabilities from the balance sheet.
Pro forma for the $42.6 million upfront payment, Kyntra held cash, cash equivalents, investments, and accounts receivable of $53.1 million as of 30 June 2026. The company expects that position to fund operations into the fourth quarter of 2027, providing a runway of approximately five quarters from the date of the announcement.
Pipeline milestones ahead
The balance sheet restructuring clears the decks ahead of what the company has positioned as a catalyst-rich period for its pipeline. Chief executive Thane Wettig highlighted two near-term readouts. FG-3246, an antibody-drug conjugate targeting CD46 in metastatic castration-resistant prostate cancer, is the company's description of a potential first-in-class asset; interim Phase 2 data are expected in the fourth quarter of 2026. Separately, Kyntra plans to initiate a pivotal Phase 3 trial of roxadustat in anaemia associated with lower-risk myelodysplastic syndromes in the same period, a move that would represent a significant expansion of the drug's approved indications.
Roxadustat is already approved across Europe, Japan, China and several other markets for anaemia in chronic kidney disease, providing a royalty stream that underpins the Astellas payment mechanism and gives Kyntra a degree of commercial revenue visibility that pure-play clinical-stage companies lack.
The ADC landscape in prostate cancer is growing competitive. Several companies are advancing CD46-targeted and other surface-antigen-directed conjugates. Investors will scrutinise the interim FG-3246 data closely, particularly response rates and safety signals in a patient population that has typically received multiple prior lines of therapy. The royalty restructuring, by reducing fixed payment obligations and linking residual payments to actual revenue, reduces financial drag during what remains a critical clinical development window for the company.
With cash extended into late 2027 and two potential data readouts in the coming months, Kyntra enters the final quarter of 2026 in a more stable financial position than it occupied at the start of the year.